Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Why It Matters
Standardized certification raises the quality of field interactions, directly boosting drug launch effectiveness and protecting patient safety, making it a strategic priority for biotech firms and investors.
Key Takeaways
- •ACMA sets standardized certification for pharma field professionals.
- •Lack of uniform training leads to inconsistent drug information to physicians.
- •Over 1,000 biotech firms now adopt ACMA certifications for staff.
- •New PAX certification becomes industry standard for prior‑authorization specialists.
- •Certified medical affairs improve compliance, patient safety, and launch success.
Summary
In the latest episode of “The Business of Biotech,” host Ben Comr talks with Dr. William Soliman, founder and CEO of the Accreditation Council for Medical Affairs (ACMA) and CIO of White Mana Capital Partners, about why many drug launches fall short and how a new certification framework can change that.
Soliman explains that before ACMA, pharmaceutical sales reps, medical science liaisons, and prior‑authorization specialists operated without any industry‑wide credential, resulting in uneven scientific knowledge and compliance risks. He cites that more than 65% of U.S. clinical research is funded by pharma, yet the professionals delivering that data often lack a uniform competency baseline.
Using a barber‑license analogy, Soliman argues that just as barbers must be licensed for safety, medical‑affairs staff need accredited training. He highlights ACMA’s board‑certified Medical Affairs Specialist program, the PAX (Prior Authorization Certified) credential, and CE‑credit‑eligible courses for nurses and regulators, noting that over 1,000 biotech and pharma companies now partner with ACMA.
The growing adoption of ACMA standards promises more accurate physician education, smoother insurance navigation, and higher launch success rates, while reducing regulatory exposure. For investors and executives, the certification trend signals a measurable lever to de‑risk product rollouts in an increasingly complex therapeutic landscape.
Comments
Want to join the conversation?
Loading comments...